{"id":"dexamethasone-nk-1-ra-5-ht3-ra","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Constipation"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Hyperglycemia (dexamethasone-related)"},{"rate":null,"effect":"Insomnia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Dexamethasone is a glucocorticoid that reduces inflammation and CINV through multiple pathways. NK-1 receptor antagonists block substance P signaling in the chemoreceptor trigger zone and vomiting center. 5-HT3 receptor antagonists (ondansetron-class agents) block serotonin signaling at peripheral and central sites. Together, these three mechanisms target complementary pathways to prevent acute and delayed CINV in patients receiving highly emetogenic chemotherapy.","oneSentence":"This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:09:14.133Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy"}]},"trialDetails":[{"nctId":"NCT06331520","phase":"PHASE3","title":"NEPA Combined With Olanzapine, Dexamethasone-sparing for the Effect of CINV in Patients Receiving HEC Regimens","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2024-05-01","conditions":"Chemotherapy-induced Nausea and Vomiting, Highly Emetogenic Chemotherapy","enrollment":627},{"nctId":"NCT04437017","phase":"PHASE3","title":"Olanzapine or Dexamethasone, With 5-HT3 RA and NK-1 RA, to Prevent CINV","status":"COMPLETED","sponsor":"Fifth Affiliated Hospital, Sun Yat-Sen University","startDate":"2020-02-03","conditions":"Chemotherapy-induced Nausea and Vomiting","enrollment":557}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Acidocont","Deronil","Dexacortal","Desameton","Fluprednisolone"],"phase":"phase_3","status":"active","brandName":"Dexamethasone+NK-1 RA+5-HT3 RA","genericName":"Dexamethasone+NK-1 RA+5-HT3 RA","companyName":"Fifth Affiliated Hospital, Sun Yat-Sen University","companyId":"fifth-affiliated-hospital-sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This triple-agent combination blocks chemotherapy-induced nausea and vomiting (CINV) through corticosteroid anti-inflammatory action, neurokinin-1 receptor antagonism, and serotonin 5-HT3 receptor antagonism. Used for Chemotherapy-induced nausea and vomiting (CINV) prevention in patients receiving highly emetogenic chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}